AZNAstraZenecaSigning up patients
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 2,130 (planned)
- Started
- Feb 3, 2026
- Main results expected
- Aug 16, 2029
- Fully finished
- Oct 27, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) (Cohort 1 and Cohort 2)
Measured over: Up to approximately 5 years
Overall Survival (OS) (Cohort 1)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07431281 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC